Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).

Overview of attention for article published in Journal of Clinical Oncology, October 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 2 news outlets
twitter: 72 X users

podcasts: 1 podcast

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 93 X posts from 72 X users, with an upper bound of 582,564 followers.

RT @DrRanaMcKay: Finally published. Data in a response adaptive IO strategy in RCC. Lower CR rates. Lower rates of CR/PR conversion. Speaks…

RT @ASCO_pubs: Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma (the OMNIVORE study) https://t.co/6f25m60A…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 89 additional X posts.